Therefore, the presence of patients with AD having comorbid anxiety/depressive disorders in a study group may be an important factor influencing findings of DAT availability, but previous brain imaging studies could not exclude these confounding factors [7–9, 28]. Here, SLC6A3 is linked to depressive disorder.